Clinical trial
Efalizumab for Moderate to Severe Atopic Dermatitis
NCT00226057 · Oregon Health and Science University, Other · Completed
Key facts
| NCT number | NCT00226057 |
|---|---|
| Title | Efalizumab for Moderate to Severe Atopic Dermatitis |
| Official title | Efalizumab for Moderate to Severe Atopic Dermatitis - A Phase I Pilot Study in Adults |
| Lead sponsor | Oregon Health and Science University, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Dermatitis, Atopic |
| Intervention type | Drug |
| Interventions | Raptiva |
| Enrollment | 10 |
| Start date | Jun 1, 2005 |
| Primary completion | Nov 1, 2005 |
| Completion | May 1, 2006 |
| First posted | Sep 26, 2005 |
| Last update posted | Jan 3, 2020 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: